Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients
出版年份 2014 全文链接
标题
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients
作者
关键词
-
出版物
CANCER
Volume 120, Issue 24, Pages 3923-3931
出版商
Wiley
发表日期
2014-08-09
DOI
10.1002/cncr.28953
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice
- (2013) Marta Garcia et al. BJU INTERNATIONAL
- VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
- (2013) P Orlandi et al. BRITISH JOURNAL OF CANCER
- Castrate-resistant prostate cancer
- (2013) Song Zhao et al. CURRENT OPINION IN UROLOGY
- Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer
- (2013) Irene Cardillo et al. Future Oncology
- Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2013) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
- (2013) Ian F Tannock et al. LANCET ONCOLOGY
- Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk Clinically Localized Prostate Cancer
- (2013) J. Vuky et al. ONCOLOGIST
- Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
- (2013) John Araujo et al. Cancer Management and Research
- Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer
- (2012) Noel W. Clarke BJU INTERNATIONAL
- Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis
- (2012) L. Eng et al. CLINICAL CANCER RESEARCH
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
- (2011) G. Sonpavde et al. ANNALS OF ONCOLOGY
- Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer – Review of the literature
- (2011) T. Nelius et al. CANCER TREATMENT REVIEWS
- Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?
- (2011) Nicolas Penel et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer
- (2011) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer
- (2010) Joel Picus et al. CANCER
- Metronomic Chemotherapy for Metastatic Prostate Cancer
- (2010) Andrea Fontana et al. DRUGS & AGING
- Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Yang-Min Ning et al. JOURNAL OF CLINICAL ONCOLOGY
- METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER
- (2010) Andrea Fontana et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
- (2009) A. Fontana et al. CLINICAL CANCER RESEARCH
- Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
- (2009) A. Calleri et al. CLINICAL CANCER RESEARCH
- The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors
- (2009) L. Jain et al. MOLECULAR CANCER THERAPEUTICS
- Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents
- (2008) Yuval Shaked et al. CANCER CELL
- Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials
- (2008) Scott D. Solomon et al. CIRCULATION
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now